ArticleCell reports. Medicine2023
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2025Article
- NUF2 and NEK2 promote malignant progression of gallbladder cancer by remodeling the extracellular matrix.Carcinogenesis · 2025Article
- NEK2 promotes the progression of osteosarcoma through the AKT/p-AKT pathway and interacts with FoxM1.Medical oncology (Northwood, London, England) · 2025Article
- INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling.Acta pharmacologica Sinica · 2025Article
- NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury.ASPET discovery · 2025Article
- Role of NEK2 in tumorigenesis and tumor progression.Trends in molecular medicine · 2025Review
- NEK2 is a potential pan-cancer biomarker and immunotherapy target.Discover oncology · 2024Article
- NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy.Heliyon · 2024Article
- Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.Cell reports. Medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
29 authors at 6 institutions in 1 country.
Yan ChengMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Fumou SunMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Daisy V AlapatDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Visanu WanchaiMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
David MeryMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Wancheng GuoMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Huojun CaoIowa Institute for Oral Health Research, Division of Biostatistics and Computational Biology, Department of Endodontics, University of Iowa College of Dentistry, Iowa City, IA 52242, USA.
Yuqi ZhuDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Cody AshbyDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Michael Anton BauerDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Intawat NookaewDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Eric R SiegelDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jun YingDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jin-Ran ChenArkansas Children's Nutrition Center, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.
Dongzheng GaiMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Bailu PengMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Hongwei XuMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Clyde BaileyMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Samer Al HadidiMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Carolina SchinkeMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Sharmilan ThanendrarajanMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Maurizio ZangariMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Marta ChesiDepartment of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
P Leif BergsagelDepartment of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
Frits van RheeMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Siegfried JanzDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Guido TricotMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
John D ShaughnessyMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Fenghuang ZhanMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Electronic address: fzhan@uams.edu.
Winthrop Rockefeller Foundation · USUniversity of Arkansas for Medical Sciences · USMayo Clinic in Arizona · USUniversity of Iowa · USArkansas Children's Nutrition Center · USMedical College of Wisconsin · US
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MPrevention of MGUS Progression to MM by Modulating the Bone Marrow MicroenvironmentU54CA272691 · NCI · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI John Damian Shaughnessy · 2023 to 2026
$6.1MDefining genetic pathways of plasma-cell neoplasiaR01CA151354 · NCI · UNIVERSITY OF IOWA · PI JANZ, SIEGFRIED · 2010 to 2022
$3.9MTowards a better understanding of the critical role and therapeutic potential of drug resistant genes in multiple myelomaR01CA236814 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI FENGHUANG ZHAN · 2020 to 2026
$2.5Mpreclinical optimization of BCMA directed T cell therapyR01CA272426 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel, Marta Chesi · 2023 to 2026
$2.5MInstitutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3MCredentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple MyelomaR01CA234181 · NCI · MAYO CLINIC ARIZONA · PI CHESI, MARTA · 2019 to 2023
$1.9MAutomated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health RecordR42CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2016 to 2017
$1.5MAutomated Dynamic Lists for Efficient Electronic Health Record ManagementR41CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2013 to 2014
$422kNCATS NIH HHS KL2 TR003108NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA151354NCI NIH HHS R01 CA234181NCI NIH HHS R01 CA236814NCI NIH HHS R01 CA272426NCI NIH HHS R41 CA180190NCI NIH HHS R42 CA180190NCI NIH HHS U54 CA272691
Abstract
Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor microenvironmental cells is associated with MM growth suppression. The absence of NEK2 leads to both fewer tumor-associated macrophages (TAMs) and inhibitory T cells. NEK2 expression in myeloid progenitor cells promotes the generation of functional TAMs when stimulated with MM conditional medium. Clinically, high NEK2 expression in MM cells is associated with increased CD8
Indexed as
Multiple MyelomaAnimalsB7-H1 AntigenCell Line, TumorMiceMyeloid Progenitor CellsT-LymphocytesTumor MicroenvironmentB7-H1 Antigenbone marrow microenvironmentcombination therapyimmune checkpoint blockadeinterferon gamma gene signaturemultiple myelomamyeloid-derived suppressive cellsNEK2PD-L1T cell immunitytumor-associated macrophages
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.